This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Buckley, B. M Search for Related Content Social Bookmarking                         What's this?

Review: Lipids and stroke

Department of Pharmacology and Therapeutics, University College Cork, 2200 Cork Airport Business Park, Kinsale Road, Cork, Ireland, brenbuck{at}ucc.ie

Stroke is the third leading cause of death in adults. Although vascular disease is the prime contributor to its pathogenesis, dyslipidaemia is not unambiguously established as a risk factor for stroke in the same way that it is for coronary artery disease. Non-statin treatments of dyslipidaemia have not been shown clearly to help in preventing stroke. However, large clinical trials of treatment with statins over a number of years have demonstrated that these drugs decrease ischaemic stroke rates in persons at risk. Whether this reflects the efficacy of statins in lowering low density lipoprotein-cholesterol (LDL-c) concentrations alone or whether additional mechanisms may apply is not clear.

Key Words: stroke • risk factors • cholesterol • LDL • HDL • triglycerides • lipoprotein fibrate • HMG-CoA reductase inhibitor • statin.

The British Journal of Diabetes & Vascular Disease, Vol. 3, No. 3, 170-176 (2003)
DOI: 10.1177/14746514030030030301


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?